Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA generics chief moves to new role

This article was originally published in Scrip

Executive Summary

Gary Buehler, who has been the head of the US Food and Drug Administration’s Office of Generic Drugs for nearly a decade, is moving to a new role within the agency. In his new position, Mr Buehler will play a key role in negotiations and activities relating to generic drug user fees.

You may also be interested in...



EU Makes ISO Format Mandatory For Side-Effect Reporting From June 2022

Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.

UK Heads For Full Trial Transparency

The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.

UK Multiple Myeloma Patients Allowed Early Access To Sanofi’s Isatuximab

The UK scheme allows patients with early access to promising new unlicensed medicines when there is a clear unmet medical need.

UsernamePublicRestriction

Register

SC007210

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel